Answers are grounded in this paper and cite their sources.
Complete, reproducible search strategies for the ten bibliographic databases and three trial registries searched in a systematic review and meta-analysis of amoxicillin dosing frequency and daily dose within tegoprazan-based dual therapy for Helicobacter pylori eradication (protocol prepared according to PRISMA-P 2015; PROSPERO registration in progress). Contents of this dataset (three files): 1. search_strategy_all_databases.md — full search strings for PubMed/MEDLINE, Embase, Cochrane CENTRAL, Web of Science Core Collection, Scopus, CBM, CNKI, Wanfang Data, VIP and SinoMed, plus ClinicalTrials.gov, ChiCTR and WHO ICTRP, with Chinese-language equivalents for the domestic databases. 2. search_strategy_pubmed.md — the exact PubMed line-by-line strategy (blocks #1–#7) ready to re-run, together with the supplementary block used to identify reduced-dose regimens (amoxicillin below 3.0 g/day). 3. 00_README.md — database list, host/platform used, planned search date, deduplication and PRISMA 2020 recording procedure. The strategies combine controlled vocabulary (MeSH/Emtree) with free-text terms for Helicobacter pylori, tegoprazan (including CJ-12420 and potassium-competitive acid blocker synonyms), amoxicillin, and dual-therapy concepts. No language or date limits are applied. Reference-list hand-searching and citation tracking of included studies and of recent syntheses are also described. The strategies were drafted and deposited before formal screening began; they had not been run against the live databases at the time of deposit. This dataset is deposited to satisfy the PROSPERO requirement that the full search strategy be publicly available and reproducible; the registry record will cite this DOI.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: